Interim results from the first-in-human clinical trial of Adct-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory diffuse large B-cell lymphoma
Radford, John A Kahl, S Hamadani, M Carlo-Stella, C Caimi, P Ardeshna, M Feingold, J He, S Reid, E Solh, M
Radford, John A
Kahl, S
Hamadani, M
Carlo-Stella, C
Caimi, P
Ardeshna, M
Feingold, J
He, S
Reid, E
Solh, M
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Radford J, Kahl B, Hamadani M, Carlo-Stella C, Caimi P, Ardeshna K, et al. Interim results from the first-in-human clinical trial of Adct-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2018;132.